Navigation Links
Anti-HIV drug use during pregnancy does not affect infant size, birth weight
Date:5/1/2012

Infants born to women who used the anti-HIV drug tenofovir as part of an anti-HIV drug regimen during pregnancy do not weigh less at birth and are not of shorter length than infants born to women who used anti-HIV drug regimens that do not include tenofovir during pregnancy, according to findings from a National Institutes of Health network study. However, at 1 year of age, children born to the tenofovir-treated mothers were slightly shorter and had slightly smaller head circumferenceabout 1 centimeter each, on averagethan were infants whose mothers did not take tenofovir.

The study authors described the findings as reassuring, noting that the study did not identify any serious safety concerns during pregnancy for tenofovir. In combination with other anti-HIV drugs, tenofovir is the first line of treatment for adults with HIV. The researchers called for additional studies to follow the children as they grow and develop, to identify any potential long term effects of the treatment. Information on Tenofovir and formulations containing tenofovir is available at http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0000198/.

The study was undertaken because earlier studies had shown laboratory animals exposed to tenofovir in the womb were smaller at birth than were their unexposed peers.

Because of its safety and effectiveness, many women who have HIV take the drug for their health, often before they become pregnant. Similarly, because the drug is so effective for adult use and because there have been no problems reported in human infants related to their mother's use of tenofovir, many physicians will prescribe it for pregnant women, both to safeguard the women's health and to prevent the virus from being passed on to their infants. However, before the current research, the drug had not been specifically studied for its potential effects on infants whose mothers took it d
'/>"/>

Contact: Robert Bock or Marianne Glass Miller
bockr@mail.nih.gov
301-496-5133
NIH/National Institute of Child Health and Human Development
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. New anti-HIV gene therapy makes T-cells resistant to HIV infection
2. Researchers report on the early development of anti-HIV neutralizing antibodies
3. Designing more effective anti-HIV antibodies
4. Peregrine reports new study from Duke shows anti-HIV potential of targeting PS on cells
5. Einstein to develop anti-HIV drug delivery system
6. Caltech scientists show why anti-HIV antibodies are ineffective at blocking infection
7. Bodys anti-HIV drug explained
8. Vitamin D supplements may protect against viral infections during the winter
9. Dog owners more likely to achieve recommended activity levels during pregnancy
10. Consuming fish during pregnancy improves offsprings cognitive development and prosocial conduct
11. Fish oil during pregnancy does not protect against excessive adipose tissue development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... transformed the energy landscape in the U.S., but ... among the energy industry, residents and agricultural interests ... that degraded water quality is a potential risk ... appears in the ACS journal Environmental Science ... colleagues point out that a major criticism of ...
(Date:4/23/2014)... from using triclosan as an antimicrobial ingredient in soaps, ... scientists are reporting new evidence that appears to support ... Chemical Research in Toxicology , found that triclosan, ... the growth of human breast cancer cells in lab ... Choi and colleagues note that hormonal imbalances seem to ...
(Date:4/23/2014)... today announced Sophie Martin of the University of Lausanne, ... Medal. The award acknowledges her work to understand the ... the cell. , Martin has been working for the ... the way in which the spatial organization of cells ... last 11 years, she has been using fission yeast, ...
Breaking Biology News(10 mins):How to avoid water wars between 'fracking' industry and residents 2In lab tests, the antimicrobial ingredient triclosan spurs growth of breast cancer cells 2EMBO Gold Medal 2014 awarded to Sophie Martin 2
... block CNS infectionA single molecular anchor that allows bacteria to ... many types of bacterial meningitis, a University of California, San ... By blocking the molecule's anchoring ability, researchers may be able ... serious infection of the central nervous system and a major ...
... cruel disease. Left untreated, prostate cancer cells often metastasize, ... that are extremely painful. , More than 80 ... with metastatic disease in their bones. But scientists know ... up housekeeping in bone tissue and produce the dense ...
... this webpage for pictures and videos! , With ... sea lilies look a lot like their garden-variety namesakes. Perhaps ... lilies stayed rooted instead of moving around like their stalkless ... a submersible research vessel at a depth of 430 meters ...
Cached Biology News:Researchers identify molecular anchor that allows bacterial invasion of central nervous system 2Researchers identify molecular anchor that allows bacterial invasion of central nervous system 3Prostate cancer uses Wnt signaling proteins to promote growth of bone tumors 2Prostate cancer uses Wnt signaling proteins to promote growth of bone tumors 3U. of Colorado researcher identifies tracks of swimming dinosaur in Wyoming 2U. of Colorado researcher identifies tracks of swimming dinosaur in Wyoming 3
(Date:1/15/2014)... is the device," Nobel laureate Herbert Kroemer famously ... found at the junctures where layers of different ... the interfaces between layers of metal oxides are ... favorites as spintronics, high-temperature superconductors, ferroelectrics and multiferroics. ...
(Date:1/15/2014)... Look inside the new Preferred Solutions® catalog ... from fluid handling to instruments to supplies. Many items ... order. , Preferred Solutions features a full selection ... model for precise flow control and dispensing to I/P® ...
(Date:1/15/2014)... This webinar will focus on EMA and ... in biosimilars. , Regulatory frameworks are evolving many countries ... the complex nature of biopharmaceuticals makes the demonstration of ... challenging. Based on the specific aspects of biosimilar drug ...
(Date:1/15/2014)... Rochester, NY (PRWEB) January 15, 2014 The ... cause a major disease. One of these latent viruses is ... is rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... the theory, a study found that RA patients have high ...
Breaking Biology Technology:A deeper look at interfaces 2Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... , KALAMAZOO, Mich., Nov. 3 Tolera Therapeutics, Inc., ... application with the United States Food and Drug Administration ... acute rejection of solid organ transplantation. TOL101 is ... and specifically target T cells, components of the immune ...
... , SOUTH SAN FRANCISCO, Calif., Nov. 3 Poniard Pharmaceuticals, ... oncology, today reported financial results for the third quarter ended ... "During the third quarter, we reached the 320th event target ... picoplatin for the treatment of small cell lung cancer. ...
... November 3 The new market research,report, ,Global ... 2014),published by MarketsandMarkets ( http://www.marketsandmarkets.com ) analyzes,the major ... identifies and analyzes,the main market drivers, restraints, and ... submarkets in different,geographic regions. , ...
Cached Biology Technology:Tolera Therapeutics Files IND Application for TOL101, Appoints O'Toole to Lead Clinical Operations 2Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 2Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 3Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 4Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 5Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 6Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 7MarketsandMarkets: Global Stem Cell and Advanced Technologies Market Worth US$ 88.3 Billion By 2014 2MarketsandMarkets: Global Stem Cell and Advanced Technologies Market Worth US$ 88.3 Billion By 2014 3
human Exodus-2 Research Focus: cytokine/growth factor Storage Temperature: -20C Shipping Temperature: 4C...
MAb to IgG2 (Fc gamma-2) IgG2 (Fc, gamma-2 epitope)...
... formulated for non-denaturing polyacrylamide and agarose gel ... solution contains a bromophenol blue tracking dye ... sample loading. EDTA has been included to ... SDS has been added to help dissociate ...
... Polyclonal Antibody Description: ... polyclonal antibody. Detects 70 kDa YAP ... blotting and immunohistochemistry. ... Storage: -20C ...
Biology Products: